Accelerated drug development for diseases with high unmet need demands patient focus without compromising scientific rigor.Precision dosing informed by physiologically-based pharmacokinetic (PBPK) models will enable inclusive clinical trials and narrow the gap between clinical development and realworld use.Early incorporation of the mass balance (MB) study is crucial to maximize the fidelity of a PBPK model-informed approach to precision dosing across populations and contexts of use in clinical development and therapeutic use.
No takes yet. Share an insight, caveat, or question.
Yeo et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: